Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study

Acer Therapeutics Inc ACER announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.
The study showed that ACER-801 was safe and well-tolerated but did not achieve statistical significance when evaluating ACER-801's ability to decrease the frequency or severity of hot flashes in postmenopausal women.
Related: Acer Therapeutics Expands ACER-801 Development Into Post-Traumatic Stress Disorder.
Hence, Acer is pausing the ACER-801 program until Acer has thoroughly reviewed the full data set.
Acer is continuing to focus on preparation for its commercial launch of OLPRUVA (sodium phenylbutyrate) for urea cycle disorders and the ongoing Phase 3 trial of EDSIVO (celiprolol) for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, subject to availability of additional capital beyond early in Q2 2023.
In December 2018, Acer entered into an exclusive license agreement with Sanofi SA SNY to acquire worldwide rights to ACER-801 (osanetant).
Price Action: ACER shares are down 39.96% at $0.9306 on the last check Friday.

Momentum80.19

Growth31.31

Quality78.92

Value47.11

Short

Medium

Long